First trimester fetal nuchal translucency

Curr Opin Obstet Gynecol. 1995 Apr;7(2):95-102. doi: 10.1097/00001703-199504000-00004.

Abstract

This review examines the development of a new method of screening for Down's syndrome based on the combination of fetal nuchal translucency thickness, maternal age and maternal serum biochemistry at 10-14 weeks of gestation. This method can potentially identify more than 80% of affected fetuses for a false-positive rate of less than 5%.

Publication types

  • Review

MeSH terms

  • Chorionic Gonadotropin / blood
  • Chorionic Gonadotropin, beta Subunit, Human
  • Chromosome Aberrations / diagnosis
  • Chromosome Aberrations / diagnostic imaging*
  • Chromosome Disorders
  • Down Syndrome / diagnosis
  • Down Syndrome / diagnostic imaging
  • Female
  • Humans
  • Maternal Age
  • Neck / diagnostic imaging
  • Peptide Fragments / blood
  • Pregnancy
  • Pregnancy Trimester, First
  • Pregnancy-Associated Plasma Protein-A / analysis
  • Prenatal Diagnosis
  • Sensitivity and Specificity
  • Ultrasonography, Prenatal*

Substances

  • Chorionic Gonadotropin
  • Chorionic Gonadotropin, beta Subunit, Human
  • Peptide Fragments
  • Pregnancy-Associated Plasma Protein-A